Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

被引:4
|
作者
Passardi, Alessandro [1 ]
Cecconetto, Lorenzo [1 ]
Dall'Agata, Monia [2 ]
Dazzi, Claudio [3 ]
Pasquini, Enzo [4 ]
Oliverio, Giovanni [4 ]
Zumaglini, Federica [3 ]
Zoli, Wainer [1 ]
Nanni, Oriana [2 ]
Milandri, Carlo [1 ]
Frassineti, Giovanni Luca [1 ]
Amadori, Dino [1 ]
机构
[1] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[2] Ist Oncol Romagnolo, Forli, Italy
[3] Santa Maria Croci Hosp, Dept Oncol, Ravenna, Italy
[4] Infermi Hosp, Dept Oncol, Rimini, Italy
关键词
D O I
10.1186/1479-5876-6-65
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Docetaxel and gemcitabine combinations have proven active for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate and compare two treatment schedules, one based on our own preclinical data and the other selected from the literature. Methods: Patients with stage IV NSCLC and at least one bidimensionally-measurable lesion were eligible. Adequate bone marrow reserve, normal hepatic and renal function, and an ECOG performance status of 0 to 2 were required. No prior chemotherapy was permitted. Patients were randomized to arm A (docetaxel 70 mg/m(2)on day 1 and gemcitabine 900 mg/m(2) on days 3-8, every 3 weeks) or B (gemcitabine 900 mg/m(2) on days 1 and 8, and docetaxel 70 mg/m(2) on day 8, every 3 weeks). Results: The objective response rate was 20% (95% CI: 10.0-35.9) and 18% (95% CI: 8.6-33.9) in arms A and B, respectively. Disease control rates were very similar (54% in arm A and 53% in arm B). No differences were noted in median survival (32 vs. 33 weeks) or 1-year survival (33% vs. 35%). Toxicity was mild in both treatment arms. Conclusion: Our results highlighted acceptable activity and survival outcomes for both experimental and empirical schedules as first-line treatment of NSCLC, suggesting the potential usefulness of drug sequencing based on preclinical models.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Docetaxel and gemcitabine combinations in non-small cell lung cancer
    Rizvi, NA
    Spiridonidis, CH
    Davis, TH
    Bhargava, P
    Marshall, JL
    Dahut, W
    Figuera, M
    Hawkins, MJ
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 27 - 31
  • [22] Docetaxel-irinotecan doublet chemotherapy as first-line therapy for advanced non-small cell lung cancer: A Phase II study
    Shamseddine, A
    Abou Mourad, Y
    Makarem, J
    Kattan, J
    Farhat, F
    Jalloul, R
    Mukaddem, W
    Taher, A
    Chehal, A
    Ghosen, M
    LUNG CANCER, 2005, 49 : S269 - S269
  • [23] Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer
    Hillerdal, Gunnar
    Sederholm, Christer
    Andersson, Kerstin
    LUNG CANCER, 2011, 71 (02) : 178 - 181
  • [24] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    LUNG CANCER, 2005, 49 : S237 - S237
  • [25] A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer
    Jiang, Haiping
    Zhang, Xiaochen
    Chen, Jing
    Zhang, Ling
    Xiong, Jianping
    Zhong, Lin
    Yu, Feng
    Qian, Jiong
    Yu, Lanfang
    Wang, Xiaoting
    Shi, Genming
    Deng, Jing
    Xu, Nong
    JOURNAL OF THORACIC DISEASE, 2014, 6 (02) : 79 - 85
  • [26] Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
    Novello, Silvia
    Falcone, Alfredo
    Crino, Lucio
    Rinaldi, Massimo
    Nardi, Mario
    De Marinis, Filippo
    Tonato, Maurizio
    Tibaldi, Carmelo
    Tinazzi, Angelo
    Russo, Francesca
    Grassivaro, Nicoletta
    Scagliotti, Giorgio Vittorio
    LUNG CANCER, 2009, 66 (03) : 327 - 332
  • [27] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gaspar, E.
    Firvida, J.
    Amenedo, M.
    Orts, D.
    Salgado, M.
    LLorca, C.
    Ramos, M.
    Perez, E.
    Cervera, J.
    Abal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Gemcitabine and docetaxel as concomitant or sequential first-line therapy of advanced non-small cell lung cancer:: Updated results of a randomized study
    Manegold, C
    Thatcher, N
    Kortsik, C
    Koschel, G
    Spengler, W
    Mezger, J
    Müller, A
    Piiz, L
    LUNG CANCER, 2005, 49 : S36 - S36
  • [29] Weekly docetaxel-gemcitabine as first-line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study.
    Kalmadi, SR
    Mekhail, T
    Adelstein, D
    Giannini, C
    Peereboom, D
    Olencki, T
    Davis, M
    Bukowski, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 675S - 675S
  • [30] Randomized multicenter phase II study with docetaxel in combination with either cisplatin or oxaliplatin as first-line treatment in patients with advanced or metastatic non-small cell lung cancer
    Atmaca, A.
    Al-Batran, S.
    Guener, T.
    Pauligk, C.
    Koepke, A.
    Bernhard, H.
    Wenzel, T.
    Banat, A. G.
    Brueck, P.
    Caca, K.
    Prasnikar, N.
    Kullmann, F.
    Jaeger, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)